Drugs / VIPIVOTIDE TETRAXETAN GALLIUM
VIPIVOTIDE TETRAXETAN GALLIUM
also known as
68 Ga-PSMA-617 · [68Ga]Ga-PSMA-617 · 68Ga-PSMA-33 · Psma-617 ga-68 · VIPIVOTIDE TETRAXETAN GALLIUM GA-68
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06437496 | Apr → Jul 2024 | prostate cancer | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03606837 | Jul 2019 → Jun 2023 | prostate cancer | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 2 | NCT03604757 | Apr 2018 → Dec 2019 | prostate cancer | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05841992 | Jul 2021 → May 2023 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04796467 | Oct 2020 → Aug 2021 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06054789 | Oct 2022 → Oct 2023 | prostate cancer | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIPIVOTIDE TETRAXETAN GALLIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650685 ↗ |
| Known as | 68 Ga-PSMA-617 | “PURPOSE: We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients.” PMID 36727866 ↗ Jan 20236“For comparison, 3 patients were additionally received 68Ga-PSMA-617 PET/CT imaging.” NCT06054789 ↗ |
| Known as | 68Ga-PSMA-33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06054789 ↗ |
| Known as | [68Ga]Ga-PSMA-617 | “Head-to-head comparison of [(68) Ga]Ga-P16-093 and [(68) Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.” PMID 34557930 ↗ Sep 20211“[68Ga]Ga-PSMA-617 (a radiolabeled PSMA-inhibitor)” PMID 41656418 ↗ Feb 2026 |
| Known as | Psma-617 ga-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650685 ↗ |
| Known as | VIPIVOTIDE TETRAXETAN GALLIUM GA-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650685 ↗ |
| Action | Inhibit | “68Ga-PSMA-617 (a radiolabeled PSMA inhibitor)” PMID 36215569 ↗ Sep 2022 |
| Modality | Diagnostic / imaging agent | “Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.” NCT04796467 ↗ |
| Route | Intravenous | “Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617.” NCT04796467 ↗ |